Federated Hermes
STLN

Federated Hermes’s Starling Oncology STLN Stock Holding History

Federated Hermes’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Buy
+3,322
New +$14K ﹤0.01% 1793
2023
Q1 		– Sell
-6,697
Closed -$11.1K – 2260
2022
Q4 		$11.1K Buy
+6,697
New +$18.8K ﹤0.01% 1859

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Federated Hermes's STLN Position: Q2 2026 in Review

Federated Hermes opened a new position in Starling Oncology (STLN) in Q2 2026: 3,322 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #1793 among its holdings. This is a return to the name: Federated Hermes previously reported a position in STLN as recently as Q4 2022.

Federated Hermes first reported a position in STLN in Q4 2022 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Federated Hermes held 3,322 shares of Starling Oncology worth $18K as of Q2 2026.
  • Starling Oncology was a new Federated Hermes position in Q2 2026.
  • Starling Oncology made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1793 holding.
  • Federated Hermes first reported a position in Starling Oncology in Q4 2022 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.